OBJECTIVE: UBE2L3 is associated with susceptibility to systemic lupus erythematosus (SLE) and rheumatoid arthritis in European ancestry populations, and this locus has not been investigated fully in non-European populations. We studied the UBE2L3 risk allele for association with SLE, interferon-α (IFN-α), and autoantibodies in a predominantly African American SLE cohort. METHODS: We studied 395 patients with SLE and 344 controls. The UBE2L3 rs5754217 polymorphism was genotyped using Taqman primer-probe sets, and IFN-α was measured using a reporter cell assay. RESULTS: The UBE2L3 rs5754217 T allele was strongly enriched in African American patients with anti-La antibodies as compared to controls, and a recessive model was the best fit for this association (OR 2.55, p = 0.0061). Serum IFN-α also demonstrated a recessive association with the rs5754217 genotype in African American patients, and the TT/anti-La-positive patients formed a significantly high IFN-α subgroup (p = 0.0040). Similar nonstatistically significant patterns of association were observed in the European American patients with SLE. Case-control analysis did not show large allele frequency differences, supporting the idea that this allele is most strongly associated with anti-La-positive patients. CONCLUSION: This pattern of recessive influence within a subgroup of patients may explain why this allele does not produce a strong signal in standard case-control studies, and subphenotypes should be included in future studies of UBE2L3. The interaction we observed between UBE2L3 genotype and autoantibodies upon serum IFN-α suggests a biological role for this locus in patients with SLE in vivo.
OBJECTIVE:UBE2L3 is associated with susceptibility to systemic lupus erythematosus (SLE) and rheumatoid arthritis in European ancestry populations, and this locus has not been investigated fully in non-European populations. We studied the UBE2L3 risk allele for association with SLE, interferon-α (IFN-α), and autoantibodies in a predominantly African American SLE cohort. METHODS: We studied 395 patients with SLE and 344 controls. The UBE2L3rs5754217 polymorphism was genotyped using Taqman primer-probe sets, and IFN-α was measured using a reporter cell assay. RESULTS: The UBE2L3rs5754217 T allele was strongly enriched in African American patients with anti-La antibodies as compared to controls, and a recessive model was the best fit for this association (OR 2.55, p = 0.0061). Serum IFN-α also demonstrated a recessive association with the rs5754217 genotype in African American patients, and the TT/anti-La-positive patients formed a significantly high IFN-α subgroup (p = 0.0040). Similar nonstatistically significant patterns of association were observed in the European American patients with SLE. Case-control analysis did not show large allele frequency differences, supporting the idea that this allele is most strongly associated with anti-La-positive patients. CONCLUSION: This pattern of recessive influence within a subgroup of patients may explain why this allele does not produce a strong signal in standard case-control studies, and subphenotypes should be included in future studies of UBE2L3. The interaction we observed between UBE2L3 genotype and autoantibodies upon serum IFN-α suggests a biological role for this locus in patients with SLE in vivo.
Authors: Stephen J Chapman; Chiea C Khor; Fredrik O Vannberg; Nicholas A Maskell; Christopher W H Davies; Emma L Hedley; Shelley Segal; Catrin E Moore; Kyle Knox; Nicholas P Day; Stephen H Gillespie; Derrick W Crook; Robert J O Davies; Adrian V S Hill Journal: Nat Genet Date: 2006-05 Impact factor: 38.330
Authors: E J Parra; A Marcini; J Akey; J Martinson; M A Batzer; R Cooper; T Forrester; D B Allison; R Deka; R E Ferrell; M D Shriver Journal: Am J Hum Genet Date: 1998-12 Impact factor: 11.025
Authors: G S Cooper; C G Parks; E L Treadwell; E W St Clair; G S Gilkeson; P L Cohen; R A S Roubey; M A Dooley Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley Journal: N Engl J Med Date: 2003-10-16 Impact factor: 91.245
Authors: S Wang; I Adrianto; G B Wiley; C J Lessard; J A Kelly; A J Adler; S B Glenn; A H Williams; J T Ziegler; M E Comeau; M C Marion; B E Wakeland; C Liang; K M Kaufman; J M Guthridge; M E Alarcón-Riquelme; G S Alarcón; J-M Anaya; S-C Bae; J-H Kim; Y B Joo; S A Boackle; E E Brown; M A Petri; R Ramsey-Goldman; J D Reveille; L M Vilá; L A Criswell; J C Edberg; B I Freedman; G S Gilkeson; C O Jacob; J A James; D L Kamen; R P Kimberly; J Martin; J T Merrill; T B Niewold; B A Pons-Estel; R H Scofield; A M Stevens; B P Tsao; T J Vyse; C D Langefeld; J B Harley; E K Wakeland; K L Moser; C G Montgomery; P M Gaffney Journal: Genes Immun Date: 2012-04-05 Impact factor: 2.676
Authors: Mark A Jensen; Karen C Patterson; Akaash A Kumar; Marissa Kumabe; Beverly S Franek; Timothy B Niewold Journal: Ann Rheum Dis Date: 2012-08-17 Impact factor: 19.103
Authors: Otsanda Ruiz-Larrañaga; Paola Migliorini; Maria Uribarri; László Czirják; Maria C Alcaro; Jokin Del Amo; Mikel Iriondo; Carmen Manzano; Sergio Escorza-Treviño; Andone Estonba Journal: Clin Rheumatol Date: 2016-03-28 Impact factor: 2.980
Authors: Yogita Ghodke-Puranik; Molly Imgruet; Jessica M Dorschner; Prakriti Shrestha; Kaci McCoy; Jennifer A Kelly; Miranda Marion; Joel M Guthridge; Carl D Langefeld; John B Harley; Judith A James; Kathy L Sivils; Timothy B Niewold Journal: Cytokine Date: 2019-01-24 Impact factor: 3.861
Authors: Yelena Koldobskaya; Kichul Ko; Akaash A Kumar; Sandra Agik; Jasmine Arrington; Silvia N Kariuki; Beverly S Franek; Marissa Kumabe; Tammy O Utset; Meenakshi Jolly; Andrew D Skol; Timothy B Niewold Journal: Clin Dev Immunol Date: 2012-07-25
Authors: Jaanam Gopalakrishnan; Kandice L Tessneer; Yao Fu; Satish Pasula; Richard C Pelikan; Jennifer A Kelly; Graham B Wiley; Patrick M Gaffney Journal: Arthritis Rheumatol Date: 2021-12-13 Impact factor: 10.995